There is finally a public document to read. Anthropic, the business behind Claude, announced its IPO filing on October 26, 2026. The form is an S-1, filed with the Securities and Exchange Commission. The shares described in it are Class A common stock.
So, can you buy ANT on Nasdaq now? Not on the strength of this announcement. ANT is the symbol Anthropic intends to use on the Nasdaq Global Select Market. The company says its registration statement is not effective yet. It hasn't announced an offering price or how many shares will be sold, either.
That can get lost on a busy news day. A filing arrives, people start discussing a possible valuation, and suddenly it sounds as if the whole deal is finished. This one isn't. What changed today is that readers have a prospectus they can inspect for themselves.
Start with the two filing dates
Remember the June news? On June 1, Anthropic said it had confidentially submitted a draft S-1 to the SEC. Its statement then said that gave it the option to go public after review, depending on market conditions and other factors.
Today's announcement is about a public filing. That's the distinction to keep in mind if you see both dates while searching for information. June wasn't a stock-market debut, and neither is October 26. They are steps along the way.
For this article, the starting points are Anthropic's own announcement and the public prospectus on the SEC website. Both are linked below. News coverage helps explain the document, but there is no need to rely on somebody else's screenshot when the source is available.
What still needs filling in?
Quite a lot of what would determine an investment decision. How many shares will be offered? At what price? How much will the company receive, and how much will go to existing holders selling stock? The prospectus has blanks where final terms would go.
Goldman Sachs and Morgan Stanley appear on the cover as lead banks. That tells us who is involved, not what return a buyer should expect. The same goes for the proposed ticker. ANT is easy to remember; it tells you nothing about whether the eventual price is reasonable.
For now, treat a valuation in a news story as a reported figure unless it is backed by the actual offering terms. Don't quietly turn an estimate into a fact. The sensible order is to understand the business, read the risks, and then look at the price once there is one to judge.
Revenue growth is only part of the story
The public filing puts financial detail behind the Claude business. TechCrunch's October 26 review of the S-1 reports first-half 2026 revenue of $16.3 billion, compared with $1.2 billion in the same period of 2025. Those figures give readers something more concrete than a user-growth anecdote or a private fundraising valuation.
The same report describes a first-half operating loss of $693 million and a net loss of $80.7 billion. Those are different measures, and they should not be tossed into a headline as though they describe the same expense. TechCrunch attributes much of the net loss to noncash accounting adjustments tied to convertible debt.
That accounting distinction does not make losses irrelevant. It means investors need to read the financial statements and their notes before deciding what a loss figure tells them. Operating performance, financing-related accounting and cash moving through the business answer different questions. None should be substituted for the others simply because one produces a more dramatic number.
Read the spending plan before admiring the growth
Anthropic's prospectus says it intends to use net proceeds for general corporate purposes, including working capital, operating expenses and capital expenditures. It specifically mentions compute and infrastructure, along with hiring and retaining skilled personnel.
That is worth pausing over. Buying an interest in an AI company means considering the cost of supplying its products as well as demand for them. Revenue can grow quickly while the business still requires substantial investment. The practical research task is to compare revenue, costs, cash flow and commitments, rather than assume that a larger customer base automatically produces cash for shareholders.
The use-of-proceeds section is also a reminder that an IPO can serve several purposes. The prospectus describes sales by Anthropic and by selling stockholders. Money from shares sold by existing holders does not go to the company. Investors should check the eventual split instead of assuming every dollar raised will fund new infrastructure.
Public shares do not mean equal control
Governance is another part of this filing that deserves more than a glance. The S-1 describes a special Class F share held through a Founder LLC, with voting power equal to 50.1% of the total on matters submitted to stockholders generally, including director elections other than the Class T directors.
Separately, the Long-Term Benefit Trust generally has authority to elect and remove the Class T directors, who will make up a majority of the authorized board. Anthropic is a Delaware public benefit corporation, and the prospectus explains how that structure relates to its AI safety mission.
A reader does not have to approve or disapprove of that design to recognize its investment consequences. Buying Class A shares would provide an economic interest without the same influence as the founders or the trust. Read the governance and capital-stock sections together. A small shareholder's expectations about control should match the rights actually being offered.
Filing is not an SEC endorsement
The SEC's investor bulletin on IPOs makes this point plainly: staff review concerns disclosure requirements, not a verdict that the investment is suitable or attractively priced. Even a declaration that a registration statement is effective does not mean the SEC approves the merits of the offering.
Anthropic's own announcement says its registration statement has not yet become effective. It also says the securities may not be sold, and offers to buy may not be accepted, before effectiveness. That language belongs beside the ticker news, not buried beneath it.
For retail investors, access is a separate issue. The SEC bulletin distinguishes receiving an allocation at the offering price from buying shares after trading begins. Those are different transactions and can involve different prices. Seeing a public filing does not guarantee an allocation through a brokerage account.
What to watch next
Start with amendments to the registration statement. Check whether the proposed terms, share count, selling-stockholder details or risk disclosures change. Read the newest document rather than a saved summary of an earlier version.
Then look at the final prospectus and any confirmed trading timetable. Avoid treating an expected date as a promise. If a valuation is reported before final terms are available, keep the attribution and the uncertainty attached to it.
The October 26 filing gives investors a better starting point for research. It does not remove the need for patience. There will be time to ask whether the business makes sense at the offered price. A decision can wait for missing information; it does not have to keep pace with the excitement of a filing day.
Watch the filing-day coverage
CNBC Television covers the public S-1 and the information investors are looking for next in the video below. This is third-party news coverage, not a recommendation from FastSwings.
This article is for general information, not personal investment advice or an offer to buy or sell securities. Information reflects the public filing and sources checked on October 26, 2026; offering details may change.
